HUTCHMED DRC (HCM)vsTeva Pharma Industries Ltd ADR (TEVA)
HCM
HUTCHMED DRC
$12.82
-2.29%
HEALTHCARE · Cap: $2.36B
TEVA
Teva Pharma Industries Ltd ADR
$37.09
+3.34%
HEALTHCARE · Cap: $42.84B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 3053% more annual revenue ($17.32B vs $549.12M). TEVA leads profitability with a 4.1% profit margin vs 3.3%. TEVA trades at a lower P/E of 61.3x. TEVA earns a higher WallStSmart Score of 49/100 (D+).
HCM
Avoid28
out of 100
Grade: F
TEVA
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+41.7%
Fair Value
$25.92
Current Price
$12.82
$13.10 discount
Intrinsic value data unavailable for TEVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 38 in profit
Conservative balance sheet, low leverage
Reasonable price relative to book value
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
0.2% revenue growth
3.3% margin — thin
Operating margin of 0.3%
Weak financial health signals
4.1% margin — thin
Operating margin of 4.0%
Premium valuation, high expectations priced in
Revenue declined 0.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : HCM
The strongest argument for HCM centers on Return on Equity, Debt/Equity, Price/Book.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.67 suggests the stock is reasonably priced for its growth.
Bear Case : HCM
The primary concerns for HCM are Revenue Growth, Profit Margin, Operating Margin. A P/E of 135.7x leaves little room for execution misses. Thin 3.3% margins leave little buffer for downturns.
Bear Case : TEVA
The primary concerns for TEVA are Profit Margin, Operating Margin, P/E Ratio. A P/E of 61.3x leaves little room for execution misses. Debt-to-equity of 2.18 is elevated, increasing financial risk.
Key Dynamics to Monitor
TEVA carries more volatility with a beta of 0.87 — expect wider price swings.
HCM is growing revenue faster at 0.2% — sustainability is the question.
TEVA generates stronger free cash flow (307M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TEVA scores higher overall (49/100 vs 28/100). HCM offers better value entry with a 41.7% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
HUTCHMED DRC
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
HUTCHMED (China) Limited discovers, develops and markets targeted immunotherapies and therapies for cancer and immune diseases globally. The company is headquartered in Central, Hong Kong.
Visit Website →Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?